Virax Biolabs Group Limited (NASDAQ:VRAX) Stock Short Interest Report for September

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 6,645 shares, a decrease of 78.2% from the September 15th total of 30,516 shares. Based on an average trading volume of 30,903 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Virax Biolabs Group from a “sell” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Virax Biolabs Group has an average rating of “Hold” and an average target price of $25.00.

Virax Biolabs Group Price Performance

Shares of Virax Biolabs Group stock traded down $0.12 during trading hours on Friday, reaching $1.87. 87,574 shares of the company’s stock were exchanged, compared to its average volume of 201,588. The business has a fifty day moving average of $2.64 and a two-hundred day moving average of $3.61. Virax Biolabs Group has a 1 year low of $1.81 and a 1 year high of $21.75.

About Virax Biolabs Group

Virax Biolabs Group Limited (NASDAQ: VRAX) is a biotechnology company focused on developing and commercializing diagnostic and immune-profiling technologies for viral diseases. Its activities are centered on tools intended to help identify infections and assess immune responses to viral pathogens.

The company’s portfolio has included molecular and immunological testing products, including ViraxClear diagnostic offerings and ViraxImmune technologies designed to evaluate T-cell responses.